top of page
Angel-Baby-IVF-Clinic-logo

Treatment

PGS (PGT-A)
Preimplantation
Genetic Screening

Pre-implantation Genetic Screening (PGS), now known as PGT-A (Preimplantation Genetic Testing for Aneuploidies), is a screening procedure used for chromosomal evaluation of embryos during an IVF cycle.

PGT-A is used as a selection tool with the goal of increasing pregnancy rates, reducing miscarriage rates, and shortening the time to a healthy live birth. Utilizing Next-Generation Sequencing (NGS) technology, our screening offers 99.9% accuracy.

S05_D1_Angel baby ivf clinic5383.jpg
Recommended for

  • Women aged 35 or older

  • Recurrent miscarriage (2 or more)

  • Repeated IVF implantation failure

  • Known chromosomal abnormalities or translocations in either partner

  • Severe male factor infertility

  • Previous pregnancy with chromosomal disorder

Candidates for screening

PGT-A is not required for every IVF cycle. Your doctor will recommend it based on your specific clinical situation. It is most beneficial when the risk of chromosomal abnormality is elevated.

What PGT-A detects

  • Chromosomal aneuploidies (missing or extra chromosomes)

  • Down syndrome (trisomy 21)

  • Edwards syndrome (trisomy 18)

  • Patau syndrome (trisomy 13)

  • Turner syndrome (monosomy X)

  • Klinefelter syndrome (XXY)

  • Large chromosomal deletions (>10Mb)

Who is PGT-A for?

What PGT-A does not detect

  • Single-gene disorders (use PGT-M / PGD for these)

  • Small chromosomal deletions (<10Mb)

  • Balanced translocations vs. normal embryos

  • Mosaicism may produce inconclusive results

PGT-A is not a guarantee of a healthy pregnancy. Amniocentesis or CVS is still recommended after successful implantation to confirm findings.

How it works

The PGT-A process

PGT-A is performed as part of an IVF cycle. The screening itself takes place after embryo culture and before transfer. Results typically take 7–14 days.

Step 1 · IVF cycle & embryo culture

Your IVF cycle proceeds as normal — ovarian stimulation, egg retrieval, ICSI fertilisation. Embryos are cultured in our controlled-environment lab for 5–6 days until they reach blastocyst stage. Only embryos that reach blastocyst are eligible for biopsy.

Duration: 5–6 days post-fertilisation​

Step 2 · Trophectoderm biopsy

Our embryologist removes 5–8 cells from the trophectoderm (the outer cell layer that becomes the placenta). The inner cell mass — which becomes the baby — is not touched. The procedure is performed under microscopic guidance by experienced embryologists.

Procedure: microsurgical, ~15 minutes per embryo​

Step 3 · Vitrification (embryo freezing)

After biopsy, all embryos are vitrified (flash-frozen) while the genetic analysis is performed. Our vitrification survival rate is 96.3% — the freeze does not compromise embryo quality.

Embryos remain safely stored during analysis​

Step 4 · NGS chromosome analysis

Biopsied cells undergo DNA extraction, amplification, and next-generation sequencing (NGS). All 23 chromosome pairs are analysed for numerical and large structural abnormalities. Each embryo receives a classification: normal (euploid), abnormal (aneuploid), or mosaic.

Results: 7–14 working days

Step 5 · Results review & transfer planning

Your doctor reviews the results with you. Only chromosomally normal (euploid) embryos are recommended for transfer. If mosaic embryos are present, your doctor will explain the options and risks. Transfer is scheduled in a subsequent cycle after endometrial preparation.

Transfer: frozen embryo transfer (FET) in a following cycle

99.8%

PGT-A Detection Rate

Exceeds

international average of 90–95%

84.4%

Pregnancy Rate (Under 35)

Single PGT-A embryo transfer

— exceeds intl avg of 62.7%

70.9%

Pregnancy Rate (All Ages)

Single PGT-A embryo transfer

— exceeds intl avg of 58.5%

Our results

Why screening matters

Research shows that more than 50% of embryos from women over 38 carry chromosomal abnormalities. Transferring these embryos leads to failed implantation, miscarriage, or — in rare cases — chromosomal conditions in the child. PGT-A removes this variable.

Implantation rate under 35 · 62.7%

Women under 35 using PGT-A achieve a 62.7% implantation rate per transfer — compared to 54% without screening. The improvement comes from transferring only euploid embryos.

Implantation rate over 42 · 53.7%

For women over 42, PGT-A raises the implantation rate from 7.4% to 53.7%. This is the most significant impact group — where aneuploidy rates are highest and screening provides the greatest benefit.

Reduced miscarriage risk

By excluding aneuploid embryos, PGT-A significantly reduces the risk of miscarriage caused by chromosomal factors — the single most common cause of early pregnancy loss.

Source: Study comparing IVF outcomes with and without PGT-A screening. Individual results may vary based on maternal age, egg and sperm quality, and other clinical factors. Consult your fertility specialist for a personalized success estimate.

S06_D1_Angel baby ivf clinic5449.jpg

Next step

Ready to take the next step?

Book a consultation with our team. We will review your history, run the necessary assessments, and give you an honest recommendation — whether that includes IVF or not.

No obligation. No pressure. Your first consultation is a clinical assessment, not a sales pitch.

bottom of page